We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients

Spotlight

View our Current Corporate Presentation here.

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

	Indication	Proof of Principle	Safety	Commercial
		Preclinical	Clinical	Marketed

Heme Malignancies
CA-4948* IRAK4	MYD88/TLR-altered NHL
CA-4948* IRAK4	AML/MDS patients w/ spliceosome mutations
Fimepinostat HDAC/PI3K	MYC-altered cancers
Immune Checkpoint Inhibitors
CI-8993** VISTA	VISTA-expressing/ infiltrated Cancers
CA-327* TIM3/PDL1	TIM3-expressing Cancers
CA-170* VISTA/PDL1	VISTA-expressing Cancers
Approved Drug
Erivedge*** Hedgehog	Basal Cell Carcinoma

Drug	Indication	Stage
Heme Malignancies
CA-4948* IRAK4	MYD88/TLR-altered NHL	Dose Optimization
CA-4948* IRAK4	AML/MDS patients w/ spliceosome mutations	Safety
Fimepinostat HDAC/PI3K	MYC-altered cancers	Clinical Activity
Immune Checkpoint Inhibitors
CI-8993** VISTA	VISTA-expressing/ infiltrated Cancers	Safety
CA-327* TIM3/PDL1	TIM3-expressing Cancers	Proof of Principle
CA-170* VISTA/PDL1	VISTA-expressing Cancers	Dose Optimization
Approved Drug
Erivedge*** Hedgehog	Basal Cell Carcinoma	Commercial

* IP licensed from Aurigene
** Option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)